Myeloid Mutations Register in R/R CML

ABL Mutation Register in Patients With ITK Relapsed or Refractory Chronic Myeloid Leukemia

NCT05080829•Grupo Cooperativo de Hemopatías Malignas

Summary

The aim of the study is to know the percentage of ABL mutations in patients with chronic myeloid leukemia that relapsed or are refractory to tyrosine-kinase inhibitors measured with a myeloid mutations panel by NGS.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•CML diagnosis by the WHO 2016 criteria
•Failure to reach cytogenetic response of Ph chromosome of 36 to 95% at 3 months or BCR/ABL \<10% at 6 months of treatment with TKI
•Progression or relapse of the disease after previous response to treatment with TKI
•Validation of adherence to treatment
•Inform consent

Exclusion Criteria

•Lack of information to complete the register
•Failure to response achievement due lack of adherence to treatment

Locations (1)

Grupo Cooperativo de Hemopatías Malignas

Huixquilucan, State of Mexico, Mexico

Key Dates

Start Date

March 1, 2021

Primary Completion Date

February 28, 2022

Completion Date

March 30, 2022

Last Updated

October 18, 2021

Enrollment

ESTIMATED participants

Conditions

Chronic Myeloid Leukaemia RecurrentChronic Myeloid Leukemia, in Relapse

Interventions

Myeloid mutations measurement

DIAGNOSTIC_TEST